Evotec SE (XSWX:EVT) Float Percentage Of Total Shares Outstanding: 99.83% (As of Jun. 28, 2026)


XSWX:EVT Evotec SE XSWX:EVT
68 GF Score
Price CHF4.50
GF Value CHF6.99
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Evotec SE Float Percentage Of Total Shares Outstanding?

Evotec SE XSWX:EVT +4.02% 68 Float Percentage Of Total Shares Outstanding is 99.83% as of Jun. 28, 2026. GuruFocus rates XSWX:EVT with a GF Score™ of 68/100 and a GF Value™ of CHF6.99 (Possible Value Trap). The stock has 5 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Evotec SE's float shares is 177.29 Mil. Evotec SE's total shares outstanding is 177.59 Mil. Evotec SE's float percentage of total shares outstanding is 99.83%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Evotec SE's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Evotec SE's Institutional Ownership is 22.14%.

XSWX:EVT
68GF Score
Evotec SE XSWX:EVT
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Evotec SE Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Evotec SE's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=177.29/177.59
=99.83%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 99.83% mean?
Evotec SE (XSWX:EVT) has a Float Percentage Of Total Shares Outstanding of 99.83% as of Jun. 28, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Evotec SE and its competitors.
Is Evotec SE's Float Percentage Of Total Shares Outstanding too high?
Evotec SE's current Float Percentage Of Total Shares Outstanding is 99.83%. Overall, Evotec SE has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evotec SE's Float Percentage Of Total Shares Outstanding compare to ZTS and UTHR?
Evotec SE's Float Percentage Of Total Shares Outstanding of 99.83% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Drug Manufacturers company?
A good Float Percentage Of Total Shares Outstanding depends on the Drug Manufacturers industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Evotec SE and its competitors. Evotec SE's current Float Percentage Of Total Shares Outstanding is 99.83%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evotec SE stock overvalued right now?
Based on GuruFocus' analysis, Evotec SE (XSWX:EVT) is currently considered Possible Value Trap. The stock's GF Value™ is CHF6.99, compared to a current price of CHF4.50 — trading 35.6% below its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 99.83%. Evotec SE's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Evotec SE (XSWX:EVT), the current Float Percentage Of Total Shares Outstanding is 99.83% as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Evotec SE (XSWX:EVT) Overvalued in 2026?

Based on GuruFocus' analysis, Evotec SE stock appears to be undervalued. The current stock price of CHF4.50 is trading 35.6% below its estimated GF Value™ of CHF6.99. GuruFocus considers Evotec SE to be Possible Value Trap.

Key valuation signals for XSWX:EVT:

  • Float Percentage Of Total Shares Outstanding: 99.83%
  • GF Value™: CHF6.99 vs. price of CHF4.50 (35.6% below fair value)
  • GF Score™: 68/100 with 5 warning signs

No single metric tells the full story. See the XSWX:EVT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Evotec SE Business Description

Address Essener Bogen 7, 22419 Hamburg, Hamburg, DEU, 22419
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
68GF Score

Get the complete analysis for XSWX:EVT

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF4.50
Price
CHF6.99
GF Value